{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-017208","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.163728+00:00","generated_at":"2026-05-17T04:30:17.826195+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kairos Pharma to Present Phase 2 Prostate Cancer Data at ESMO 2025","bullets":["On October 7, 2025, Kairos issued press release announcing ESMO Congress presentation in Berlin from October 17-21.","Presentation covers interim analysis of Phase 2 trial evaluating ENV105 (carotuximab) plus apalutamide in mCRPC.","Trial enrolling 100 men at Cedars-Sinai, City of Hope, and Huntsman Cancer Institute.","On October 1, 2025, Kairos Board approved novation agreements with Cedars-Sinai and Tracon to transfer patent licenses from Enviro to Kairos.","Transferred patents include exclusive licenses for mitochondrial DNA depletion and endoglin antagonism therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-017208","json":"https://secwatch.observer/filing/0001493152-25-017208.json","markdown":"https://secwatch.observer/filing/0001493152-25-017208.md","text":"https://secwatch.observer/filing/0001493152-25-017208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225017208/0001493152-25-017208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225017208/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T04:30:17.826195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}